Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

about

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Item

http://www.wikidata.org/entity/Q36739940

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@ast

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@en

type

Item

label

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@ast

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@en

prefLabel

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@ast

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@en

P1476

Assessment of Tumor Response a ...... nt Chemotherapy with Cetuximab

@en

P2093

Amit Rauthan

http://www.w3.org/2001/XMLSchema#string

K R Ashwin

http://www.w3.org/2001/XMLSchema#string

Poonam Patil

http://www.w3.org/2001/XMLSchema#string

S P Somashekhar

http://www.w3.org/2001/XMLSchema#string

Shabber S Zaveri

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Portal vein embolization: rationale, technique and future prospects.

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

Common side effects of anti-EGFR therapy: acneform rash.

P2888

s13193-015-0442-8

P304

11-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13193-015-0442-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27065676

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

4811818

http://www.w3.org/2001/XMLSchema#string